

Company Number: 187254

Bagenalstown Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Bagenalstown Pharmacy Limited
CONTENTS

	Page
Director and Other Information	3
Balance Sheet	4
Notes to the Financial Statements	5 - 8

Bagenalstown Pharmacy Limited
DIRECTOR AND OTHER INFORMATION

Director	Laura Phelan
Company Secretary	Gary Donohoe
Company Number	187254
Registered Office and Business Address	22 Main Street Bagenalstown Co. Carlow
Accountants	O'Neill Foley Unlimited Company Chartered Accountants The Brewhouse Abbey Quarter Kilkenny
Bankers	Bank of Ireland Parliament Street Kilkenny
Solicitors	Maguire & McErlean 80 Drumcondra Road Upper Drumcondra Dublin 9

Bagenalstown Pharmacy Limited

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	6	168,417	87,926
Current Assets			
Stocks	7	188,258	158,062
Debtors	8	285,731	181,363
Cash and cash equivalents		318,036	414,273
		792,025	753,698
Creditors: amounts falling due within one year	9	(102,424)	(100,033)
Net Current Assets		689,601	653,665
Total Assets less Current Liabilities		858,018	741,591
Capital and Reserves			
Called up share capital presented as equity		1	1
Retained earnings		858,017	741,590
Shareholders' Funds		858,018	741,591

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Bagenalstown Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 20 January 2026 and signed on its behalf by:

Laura Phelan
Director

Bagenalstown Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Bagenalstown Pharmacy Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 187254. The registered office of the company is 22 Main Street, Bagenalstown, Co. Carlow which is also the principal place of business of the company. The principal activity of the company continued to be that of operating a pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover is stated net of trade discounts, volume rebates, VAT and similar taxes and derives from the provision of goods and services falling within the company's ordinary activities.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings leasehold	-	over 25 years & 10 years
Fixtures, fittings and equipment	-	over 8 years
Motor vehicles	-	over 8 years
Computer equipment	-	over 8 years

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Bagenalstown Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Pensions

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. Annual contributions payable to the company pension scheme are charged to the Profit and Loss Account in the period to which they relate.

Financial Instruments

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Significant accounting judgements and key sources of estimation uncertainty

The directors consider the accounting estimates and assumptions below to be its critical accounting estimates and judgements:

Useful Lives of Tangible Fixed Assets

Long-lived assets comprising primarily of freeholds, short leaseholds, plant and machinery, fixtures, fittings and equipment and motor vehicles assets represent a significant portion of total assets. The annual depreciation and amortisation charge depends primarily on the estimated lives of each type of asset and, in certain circumstances, estimates of residual values. The directors regularly review these useful lives and change them if necessary to reflect current conditions. In determining these useful lives management consider technological change, patterns of consumption, physical condition and expected economic utilisation of the assets. Changes in the useful lives can have a significant impact on the depreciation and amortisation charge for the financial year. The net book value of Tangible Fixed Assets subject to depreciation at the financial year end date was €168,417 (2024: €87,926).

Impairment of Trade Debtors

The company trades with a large and varied number of customers on credit terms. Some debts due will not be paid through the default of a small number of customers. The company uses estimates based on historical experience and current information in determining the level of debts for which an impairment charge is required. The level of impairment required is reviewed on an ongoing basis. The total amount of trade debtors is €92,497 (2024: €76,729).

Impairment of Stocks

The company holds stocks amounting to €188,258 (2024: €158,062) at the financial year end date. The directors are of the view that an adequate charge has been made to reflect the possibility of stocks being sold at less than cost. However, this estimate is subject to inherent uncertainty.

4. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	26,103	12,781
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including director, during the financial year was 20, (2024 - 18).

Bagenalstown Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

6. Tangible assets

	Land and buildings leasehold €	Fixtures, fittings and equipment €	Motor vehicles €	Computer equipment €	Total €
Cost					
At 1 May 2024	141,733	213,932	24,671	58,143	438,479
Additions	-	104,561	-	2,033	106,594
At 30 April 2025	141,733	318,493	24,671	60,176	545,073
Depreciation					
At 1 May 2024	78,824	191,998	21,588	58,143	350,553
Charge for the financial year	4,469	18,297	3,083	254	26,103
At 30 April 2025	83,293	210,295	24,671	58,397	376,656
Net book value					
At 30 April 2025	58,440	108,198	-	1,779	168,417
At 30 April 2024	62,909	21,934	3,083	-	87,926

7. Stocks

	2025 €	2024 €
Finished goods and goods for resale	188,258	158,062

The replacement cost of stock did not differ significantly from the figures shown.

8. Debtors

	2025 €	2024 €
Trade debtors	92,497	76,729
Other debtors	20,000	-
Director's current account (Note 13)	113,640	-
Taxation	23,869	56,737
Prepayments	35,725	47,897
	285,731	181,363

9. Creditors

Amounts falling due within one year

	2025 €	2024 €
Amounts owed to credit institutions		
Bank overdrafts	134	354
Trade creditors	81,276	75,344
Taxation	13,464	10,015
Director's current account (Note 13)	-	6,770
Accruals	7,550	7,550
	102,424	100,033

Trade creditors include amounts owing to suppliers, who purport to include reservation of title clauses in their conditions of sales. It is not practicable to quantify this amount, or how much of it is included in stocks.

10. Pension costs - defined contribution

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Pension costs amounted to €44,763 (2024 - €112,000).

Bagenalstown Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

11. Profit and loss account

	2025	2024
	€	€
At 1 May 2024	741,590	677,676
Profit for the financial year	116,427	63,914
	<u> </u>	<u> </u>
At 30 April 2025	858,017	741,590
	<u> </u>	<u> </u>

12. Capital commitments

The company has capital commitments at the financial year-ended 30 April 2025 of €Nil (2024: €47,897).

13. Director's remuneration and transactions

	2025	2024
	€	€
Director's remuneration		
Remuneration	73,384	54,483
Pension contributions	36,000	112,000
	<u> </u>	<u> </u>
	109,384	166,483
	<u> </u>	<u> </u>

The following amounts are repayable to the director:

	2025	2024
	€	€
Laura Phelan	-	6,770
	<u> </u>	<u> </u>

14. Controlling interest

The company is owned and controlled by Laura Phelan.

15. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 20 January 2026.